Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA3417569
Max Phase: Preclinical
Molecular Formula: C45H52N4O10S
Molecular Weight: 841.00
Molecule Type: Small molecule
Associated Items:
ID: ALA3417569
Max Phase: Preclinical
Molecular Formula: C45H52N4O10S
Molecular Weight: 841.00
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC1(C)CC[C@]2(C(=O)NCC(=O)OCC#CCOc3no[n+]([O-])c3S(=O)(=O)c3ccccc3)CC[C@]3(C)[C@H](C(=O)C=C4[C@@]5(C)C=C(C#N)C(=O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]2C1
Standard InChI: InChI=1S/C45H52N4O10S/c1-40(2)17-19-45(39(53)47-27-34(51)57-21-11-12-22-58-37-38(49(54)59-48-37)60(55,56)29-13-9-8-10-14-29)20-18-44(7)35(30(45)25-40)31(50)23-33-42(5)24-28(26-46)36(52)41(3,4)32(42)15-16-43(33,44)6/h8-10,13-14,23-24,30,32,35H,15-22,25,27H2,1-7H3,(H,47,53)/t30-,32-,35-,42-,43+,44+,45-/m0/s1
Standard InChI Key: ATBHJBNVRXUIPV-GRKOGERCSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 841.00 | Molecular Weight (Monoisotopic): 840.3404 | AlogP: 5.40 | #Rotatable Bonds: 8 |
Polar Surface Area: 209.67 | Molecular Species: NEUTRAL | HBA: 12 | HBD: 1 |
#RO5 Violations: 3 | HBA (Lipinski): 14 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 12.16 | CX Basic pKa: | CX LogP: 6.54 | CX LogD: 6.54 |
Aromatic Rings: 2 | Heavy Atoms: 60 | QED Weighted: 0.20 | Np Likeness Score: 0.77 |
1. Ai Y, Kang F, Huang Z, Xue X, Lai Y, Peng S, Tian J, Zhang Y.. (2015) Synthesis of CDDO-amino acid-nitric oxide donor trihybrids as potential antitumor agents against both drug-sensitive and drug-resistant colon cancer., 58 (5): [PMID:25675144] [10.1021/jm5019302] |
Source(1):